Official websites use. Share sensitive information only on official, secure websites. We conducted a placebo-controlled randomized pilot study with the primary objective of determining safety of NR in older adults with mild cognitive impairment MCI.
The primary outcome was post-treatment change from baseline measures of cognition Montreal Cognitive Assessment, MoCA. The target NR dose was safely achieved as evidenced by a 2. MoCA and other neurocognitive and psychometric metrics remained stable throughout the study.
Other secondary outcome measures remained stable. Global methylation analyses indicated a modest NR-associated increase in DNA methylation and concomitant reduction in epigenetic age as measured by PhenoAge and GrimAge epigenetic clock analyses.
NR was well tolerated and did not alter cognition. While CBF was reduced by NR treatment, statistical significance would not have withstood multiple comparisons correction. A larger trial of longer duration is needed to determine the potential of NR as a strategy to improve cognition and alter CBF in older adults with MCI.
Mild cognitive impairment MCI refers to an intermediate cognitive state between changes that occur with normal aging and dementia.
